Introduction
The XIII Banff meeting was held October 5-10, 2015, in Vancouver, Canada, in conjunction with the annual meeting of the Canadian Society of Transplantation. A total of 451 delegates from 28 countries attended the conference, including pathologists, immunologists, physicians, surgeons, and immunogeneticists. The main aims of the 2015 conference were to review the clinical impact of the 2013 changes related to the new diagnostic criteria for antibody-mediated rejection (ABMR) (1) and to identify the next set of challenges in transplant diagnostics. Given the limitations of the current Banff system, a need for a more integrated diagnostic system, including complementary approaches as a companion to the current morphologic gold standard, are needed. Consequently, the prospects for introducing molecular diagnostics into the Banff classification were a main focus. Accordingly, the Banff 2015 conference was preceded by a full-day premeeting on "Precision Diagnostics" in transplantation. This included presentations from key opinion leaders of the American Society for Histocompatibility and Immunogenetics (ASHI) with the aim to foster collaboration between the societies in transplant diagnostics. This meeting report summarizes the main outcomes from the Banff kidney, pancreas, and vascularized composite allograft (VCA) sessions; the main conclusions from the 2015 Banff liver, heart, and lung sessions will be published elsewhere. The XIV Banff meeting will be held jointly with the Catalan Society of Transplantation in Barcelona, Spain, March 27-31, 2017.
Results From the Banff Working Groups and New Developments
Banff Working Groups (BWGs) have been formed at each of the last four Banff conferences to address and potentially modify specific aspects of the classification (2) . Their activities are dynamic and goal directed; therefore, the Banff community decided during the 2015 conference to close or suspend working groups whose work has been completed and published, in press, and/ or incorporated into the classification (isolated endarteritis, Banff Initiative for Quality Assurance in Transplantation, fibrosis, implantation biopsy, polyoma virus, C4d-negative ABMR, and glomerular lesions BWGs) (1, (3) (4) (5) (6) (7) . The BWG on highly sensitized patients presented the results of three surveys of pathologists, clinicians, and histocompatibility laboratory directors, comprising 193 centers from six continents, and revealed wide heterogeneity among participating centers regarding immune modulation/desensitization practices, timing of kidney allograft protocol biopsies, and testing and reporting of HLA antibody and donor-specific antibody (DSA) levels. The TCMR working group's main aims and related ongoing studies are detailed in Table 1 and are expected to provide novel insights by the next Banff meeting.
Four new BWGs have been formed: (i) thrombotic microangiopathy, (ii) recurrent glomerular diseases, (iii) diagnostic electron microscopy, and (iv) composite surrogate end points. The aim of the latter BWG is to build and validate a composite scoring system integrating histopathology with other relevant allograft biomarkers to predict long-term allograft outcome as a potential end point for next-generation clinical trials in the area. The currently active and new working groups and their aims, leaders, initial findings (if appropriate), and ongoing work are listed in Table 1 . As an outlook on future challenges, the Banff process founder Kim Solez gave a keynote address on tissue engineering pathology, a new pathology discipline that will likely play an increasing role in future Banff meetings, as transplant pathologists need to embrace tissue engineering pathology in the era of regenerative medicine (8) .
New Challenges in Rejection Diagnosis and Classification
During the 2015 Banff conference, there was lively discussion about diagnostic concerns regarding ABMR, T cell-mediated rejection (TCMR), and mixed rejection in renal allografts. Important new data were presented revealing the heterogeneity of clinical expression of ABMR with consequent difficulties for diagnosis. In addition, important insights were presented by ASHI members on how testing for DSAs and interpretation of results should be included in the Banff classification (Table 2 ).
Recent evidence indicates that subclinical ABMR has important clinical implications, even in non-highly sensitized patients with de novo DSAs (9) . As noted by Orandi et al, "Increasing numbers of transplant physicians are encountering this problem, which may become more common given new therapeutic agents and new organ allocation policies" (10) .
A growing number of centers perform high-risk renal transplants, thereby intensifying the need for improved assessment of subclinical ABMR (11) and the clinical implications of its kinetics and response to therapy (10) . Advances in antibody testing by multiplex bead array assays have greatly enhanced the sensitivity and precision of detection of circulating DSAs (12) . Accumulating evidence supports the concept that not all DSAs are equivalent and that DSA properties (ability to bind complement or IgG subclass), beyond simple positivity and mean fluorescence intensity, are associated with distinct outcomes and injury phenotypes in preexisting or recurrent as well as de novo DSAs (13) (14) (15) (16) (17) (18) (19) (20) . These distinct DSA properties and their relationship with distinct allograft injury patterns is also increasingly demonstrated in other solid organ transplants such as liver (21) and heart (22) . It was also noted that time course, kinetics, and properties of DSA fluctuate (15, 23) . Consequently, interpretation of studies evaluating sera at a single time point, especially late after transplantation, should be interpreted with caution because of potential selection bias (24, 25) . Despite the usefulness of multiplex bead array assays, inherent limitations, technical issues, and lack of available DSA data at the time of biopsy make diagnoses complex. It was reemphasized that nonanti-HLA DSAs can produce allograft injury alone or together with anti-HLA DSAs (26) (27) (28) . These observations raise the question of whether ABMR can be diagnosed in the absence of documented DSAs based on ABMR-related pathology only, namely, microcirculation inflammation, C4d deposition, and vasculitis with or without increased expression of DSA-associated gene sets (29, 30) .
Furthermore, many cases of ABMR in renal allografts, particularly late ABMR associated with de novo DSAs, can present as mixed ABMR and TCMR (31) . Renal allograft biopsies with microvascular inflammation plus intimal arteritis also frequently show tubulointerstitial TCMR changes (9, 32) . These cases likely represent mixed ABMR and TCMR and, not surprisingly, are often not responsive to treatment for either ABMR or TCMR alone (32, 33) . This may be related in large part to the fact that many cases of late ABMR are associated with nonadherence (34) . TCMR is also a documented predisposing factor for the future development of de novo DSAs, as demonstrated in two recent studies (9, 11) . More data are needed regarding transplant glomerulopathy (TG) or double contours with or without microcirculation inflammation in terms of disease activity and progression and thus necessity of treatment. A key question discussed during the meeting was whether patients with TG should be treated for active ABMR or whether it should be accepted that these patients will progress to graft loss regardless of treatment. A study by Kahwaji et al (35) showed in a small cohort of patients, all with TG, that those with active microvascular invasion (MVI) were significantly more likely to show stabilization of graft function with intravenous immunoglobulin (IVIG) and rituximab than patients with similar histology who were not treated, whereas patients with TG without active MVI did not benefit from treatment with IVIG and rituximab. The findings suggest that the decision as to whether to treat patients with TG, particularly those with DSAs, should depend on whether there is concurrent active MVI. More recently, a pilot randomized control trial showed that patients with chronic ABMR that responded to complement blockade eculizumab by improved GFR were the ones that had complement (C1q binding) circulating anti-HLA DSAs at the time of diagnosis (36) . This important issue will be addressed further at Banff 2017. Comprehensive typing of recipient and donor is required to determine presence of HLA-DSA (HLA-A, -B, -C, -DRB1, -DRB3/4/5, -DQA1, -DQB1, -DPA1, -DPB1). Determine DSA specificity at the allelic level (including DQA and DQB and for other loci when allelic-specific antibodies are present). Recognize the assay limitations and minimize the inherent issues with reagents and patient sera when DSA specificity and level are considered: DSA, donor-specific antibody.
DSA Against HLA or Other Antigens in the Diagnosis of ABMR
The Banff 2013 classification requires the presence of "serologic evidence of DSA against HLA or other antigens" (criterion 3) for diagnosis of both acute/active and chronic active ABMR; however, peritubular capillary C4d deposition is highly specific for DSA and potentially identifies antibodies against endothelial antigens and DSA currently not tested for in many laboratories (e.g. antibodies to HLA DP, non-HLA antigens). Furthermore, a recent study showed similar graft outcomes, at least in chronic active ABMR, in cases with C4d or DSA and those with C4d and DSA (37) . The attendees of kidneyspecific sessions at Banff 2015 were polled as to whether the requirement for DSA for diagnosis of ABMR can be waived in biopsies showing both morphologic evidence of acute or chronic tissue injury (as defined in criterion 1 of the Banff 2013 classification for acute/active and chronic active ABMR, respectively) and C4d staining in peritubular capillaries; however, the opinion of the majority of the Banff panel (with some dissenters) was that this was not warranted by the current data. It was instead decided to add the following phrase to the classification for both acute/active and chronic active ABMR, as a corollary to criterion 3: "Biopsies meeting the above histologic criteria and showing diffuse or focal linear peritubular capillary C4d staining on frozen or paraffin sections are associated with a high probability of ABMR and should [undergo] prompt expedited DSA testing.". Table 3 summarizes this new addition to the classification, and the complete and most updated Banff classifications for renal allograft diagnoses are shown in Table 3 .
A set of transcripts (DSA-specific transcripts [DSASTs]) was determined to be differentially expressed in renal allograft biopsies from DSA-positive versus -negative patients (29), a finding that was later confirmed independently at a different center (30 
Chronic Active TCMR and Interstitial Inflammation in Areas of Interstitial Fibrosis and Tubular Atrophy
The most recent Banff criteria for chronic active TCMR (38) list only vascular lesions (arterial intimal fibrosis with mononuclear cell infiltration within the sclerotic intima; transplant arteriopathy) ( Table 3 ). This is likely neither complete nor fully accurate; however, sufficient data are currently not available to properly define this diagnosis.
Interstitial inflammation in areas of interstitial fibrosis and tubular atrophy (i-IFTA) was discussed among participants of the Banff meeting as a potential lesion of chronic active TCMR. Although the association of i-IFTA with decreased graft survival is well documented (39) (40) (41) , the pathogenesis of i-IFTA and to what extent this represents a manifestation of TCMR is much less clear. Similarly, the significance of tubulitis in atrophic tubules is unclear. Gene expression studies on microdissected foci of i-IFTA might help assess this. In light of the established deleterious effect on graft survival of i-IFTA and IFTA with Banff inflammation (i) score >0, it was agreed that i-IFTA should be included as part of the Banff lesion scoring. Moreover, i-IFTA should be graded as mild, moderate, or severe based on whether it involves 10-25%, 26-50%, or >50%, respectively, of the scarred cortical tissue (Table 4 , and supplementary material for scoring criteria). Note that the extent of i-IFTA is not analogous to the Banff total inflammation score, the latter representing the sum of inflammation in scarred and nonscarred areas of the cortex. Consequently, it was decided to modify the Banff 2007 criteria by adding a statement (Table 3 , category 4), reflecting findings that lesions of transplant arteriopathy may represent chronic active ABMR (42) as well as TCMR-also shown in experimental studies (43)-and that chronic active TCMR may also be manifest in the tubulointerstitial compartment.
During the postmeeting discussion, it was clearly articulated that further studies are needed to understand the significance of i-IFTA in the context of chronic active TCMR before i-IFTA can be included as a diagnostic criterion. In particular, the ongoing work of the borderline/ TCMR BWG is expected to generate relevant data in this context.
Prospects for Adopting Molecular Pathology in Renal Allograft Diagnosis
As part of the 2013 revision of the Banff classification for diagnosing ABMR, molecular assessment of transcripts indicative of endothelial injury in the renal allograft biopsy was added as a potential diagnostic criterion (1); however, there is no consensus on which transcripts are diagnostic or on the criteria for positivity. Standards for platforms, methods, and reproducibility for such molecular diagnostic assays have not yet been set; such standards are a requirement for robust clinical validation and adoption in diagnostic pathology laboratories. During the 2015 Banff premeeting on "Precision Diagnostics in Transplantation," current knowledge in the area of molecular transplant diagnostics was reviewed. State-ofthe-art presentations on molecular diagnostics in allograft biopsies and body fluids revealed that significant commonalities exist with regard to the molecular phenotype in transplant biopsies from different organ types (44) . In addition, overlap exists with molecular signatures found in body fluids (45) . In contrast, there is considerable heterogeneity among published studies with regard to Biopsies suspicious for ABMR on the basis of meeting criteria 1 and 2 should prompt expedited DSA testing C4d staining without evidence of rejection All three features must be present for diagnosis how the molecular phenotype has been assessed and applied as a potential diagnostic and/or predictive tool (46) . Over the last decade, transplant biopsies, blood, and urine have been studied comprehensively, primarily using transcriptomics, and have led to novel insights into the molecular phenotypes of organ transplants (47) (48) (49) (50) (51) (52) (53) . Current ongoing studies-for example, the INTERCOM studies (47,48)-are assessing a molecular microscope approach in real time for examining kidney allograft biopsies and comparing the gene expression classifiers and diagnosis to the current gold standard histopathology. This represents a step forward and will generate important results to help guide integration of molecular analysis with morphology. Accordingly, at the 2015 Banff meeting, converging opinion was supported by recent data (50,53) that molecular transplantation pathology is at the point where it can be translated into clinically relevant and applicable diagnostic tools. The obstacles to be overcome lie in (i) the lack of a true diagnostic gold standard against which new molecular diagnostics can be compared and calibrated (there is no gold standard for serology or histology either); (ii) the fact that data have been generated from heterogeneous cohorts with diagnostic labels assigned based on different iterations of the Banff classification; (iii) the absence of completed prospective, controlled, randomized validation studies; and (iv) the lack of agreement on the transcripts to be measured and how to measure them.
Most disease processes operating in organ transplants represent a spectrum of certain biological processes. Accordingly, our current diagnostic criteria (e.g. for TCMR and ABMR) are built on semiquantitative diagnostic thresholds of lesions associated with a certain phenotype. Such thresholds aim to represent the optimal trade-off between side effects of enhanced treatment Lesions of chronic, active ABMR can range from primarily active lesions with early TG evident only by EM (cg1a) to those with advanced TG and other chronic changes in addition to active microvascular inflammation. In the absence of evidence of current/recent antibody interaction with the endothelium (those features in the second section of Table 3 ), the term "active" should be omitted; in such cases, DSAs may be present at the time of biopsy or at any previous time after transplantation. At least moderate mesangial matrix increase in up to 25% of nonsclerotic glomeruli mm2
At least moderate mesangial matrix increase in 26-50% of nonsclerotic glomeruli mm3
At least moderate mesangial matrix increase in >50% of nonsclerotic glomeruli (Continued ) (i.e. overimmunosuppression) and the detrimental impact of further disease progression (i.e. underimmunosuppression). A potential path forward would be to generate consensus in molecular transplant diagnostics regarding which molecules are assessed or quantified in what settings (Table 5 ) and then to develop clinically relevant diagnostic thresholds through retrospective and prospective multicenter validation studies based on standardized assessment of the same molecular lesions in the same clinical context. This approach would be analogous to the Banff consensus process in 1991 for morphologic lesions. Previous research revealed strong associations between certain molecular pathways and wellestablished Banff histologic lesions (Figure 1 ). These key molecular pathways can be represented and thus assessed by relatively few molecules from each pathway, either through quantification of respective gene sets or through summarizing such genes in weighted equations as diagnostic classifiers. Generating consensus for sets of molecules or classifiers reflecting certain biological or disease processes related to the established histologic Banff lesions would enable us to assess and validate their clinical value. In this regard, the most robust evidence is currently available for the association Mild to moderate PAS-positive hyaline thickening in at least one arteriole ah2
Moderate to severe PAS-positive hyaline thickening in more than one arteriole ah3
Severe PAS-positive hyaline thickening in many arterioles Alternative quantitative criteria for hyaline arteriolar thickening: aah score aah0 No typical lesions of calcineurin inhibitor-related arteriolopathy aah1
Replacement of degenerated smooth muscle cells by hyaline deposits in only one arteriole, without circumferential involvement aah2
Replacement of degenerated smooth muscle cells by hyaline deposits in more than one arteriole, without circumferential involvement aah3
Replacement of degenerated smooth muscle cells by hyaline deposits with circumferential involvement, independent of the number of arterioles involved. Quantitative criteria for vascular fibrous intimal thickening: cv score cv0 No chronic vascular changes cv1
Vascular narrowing of up to 25% luminal area by fibrointimal thickening cv2
Vascular narrowing of 26-50% luminal area by fibrointimal thickening cv3
Vascular narrowing of >50% luminal area by fibrointimal thickening Quantitative criteria for interstitial fibrosis: ci score ci0 Interstitial fibrosis in up to 5% of cortical area ci1
Interstitial fibrosis in 6-25% of cortical area (mild interstitial fibrosis) ci2
Interstitial fibrosis in 26-50% of cortical area (moderate interstitial fibrosis) ci3
Interstitial fibrosis in >50% of cortical area (severe interstitial fibrosis) Quantitative criteria for tubular atrophy: ct score ct0 No tubular atrophy ct1 Tubular atrophy involving up to 25% of the area of cortical tubules (mild tubular atrophy) ct2
Tubular atrophy involving 26-50% of the area of cortical tubules (moderate tubular atrophy) ct3
Tubular atrophy involving in >50% of the area of cortical tubules (severe tubular atrophy) aah, hyaline arteriolar thickening; ah, arteriorlar hyalinosis; cg, glomerular double contours; ci, interstitial fibrosis; ct, tubular atrophy; cv, vascular fibrous intimal thickening; EM, electron microscopy; g, glomerulitis; GBM, glomerular basement membrane; i, inflammation; i-IFTA, interstitial inflammation in areas of interstitial fibrosis and tubular atrophy; mm, mesangial matrix expansion; PAS, periodic acid-Schiff; ptc, peritubular capillaritis; PTC, peritubular capillary; t, tubulitis; v, intimal arteritis. among antibody-mediated injury; microcirculation inflammation; and increased expression of endothelial, NK cell, and inflammation-associated transcripts in the allograft (29, 54, 55, 56) .
Discussion of the above approach took place at the 2015 Banff meeting and continued afterward via e-mail exchange among the key opinion leaders. From these interactions, key next steps toward adopting molecular diagnostics into transplantation pathology were identified and are summarized (Table 6 ):
1. The overwhelming majority of those who commented support pursuing the generation of molecular consensus gene sets (or classifiers) from the overlap between published gene lists, adding key genes based on pathogenesis-based association with the main clinical indications and phenotypes (TCMR, ABMR). 2. More collaborative multicenter studies are needed (Table 6 ) to close existing knowledge gaps before Banff can "officially" adopt specific molecular diagnostics as part of the classification. 3. Consensus must be generated on gene sets, which can be studied further in a multicenter setting. 4 . Results from such studies should be reviewed at future Banff meetings as part of an ongoing consensus process for molecular diagnostics.
Once consensus for gene sets and/or classifiers for molecular biopsy assessment is achieved, prospective and retrospective validation trials can be initiated. Similar to the validation of histologic Banff lesions and diagnostic rules established in 1991, only multicenter validation of different diagnostic approaches with hard clinical end points (e.g. allograft survival, response to treatment) can establish clinically useful diagnostic thresholds. In the absence of a true diagnostic gold standard, adoption of molecular diagnostics can only be accomplished in a stepwise and iterative approach over time including constant revisiting and refinement of current molecular consensus as new knowledge emerges.
Summary of the Banff Pancreas Session
Three main topics (Table 7) were emphasized at the pancreas transplant session: (i) discussion of controversial morphologic aspects, (ii) progress made with the working groups since the 2013 meeting, and (iii) encouragement of data regarding the utility of endoscopic duodenal cuff biopsies as surrogates of biopsies of the pancreas transplant. Data were presented showing that a normal duodenal cuff biopsy accurately predicts absence of TCMR in the pancreas parenchyma. A study of duodenal cuff biopsies showed a high incidence of cytomegalovirus infection in these samples that we do not know how to interpret at this stage. Furthermore, data from detailed morphologic studies on pale acinar nodules in native and transplant pancreas biopsies, which are still of unclear etiology and clinical significance, were presented (57) . A study was presented at the Banff session that showed simultaneous pancreas and kidney transplant biopsies demonstrating high concurrence between acute ABMR in both organs and significant discrepancy between organs for TCMR. Modifications to the Banff pancreas allograft pathology schema were made after consensus was reached following e-mail circulation to the BWG for Pancreas Pathology and via discussions during the meeting. Main updates include incorporation of acute ABMR grading, improved definitions for TCMR and ABMR, specification of vascular lesions, and inclusion of b cell islet toxicity in the category of islet pathology. In the second part of the session, key opinion leaders discussed morphologic and clinical aspects of graft loss in whole pancreas transplants as well as islet transplantation. It was concluded that better understanding of the etiology of graft loss represents an unmet need. This will require systematic integration of morphologic (pathology), serologic (DSAs and autoantibodies), and clinical-functional (e.g. oral glucose tolerance test) parameters for studying the cause and incidence of pancreas transplant failure.
Summary of the VCA Session
The VCA session included speaker presentations and discussion. Focal points of the former were ABMR after face transplantation (58) , graft vasculopathy in the skin (59), cutaneous changes among transplant patients, and the expansion of the Banff VCA scoring system. The discussion included challenges to the Banff VCA system, immunohistochemistry markers, specimen adequacy, and differential diagnoses. Collaborative efforts were discussed, and the working group concentrated on the standardization of a document for the retrospective and prospective collection of data. The group will reconvene at an international workshop on VCA histopathology with the goals of continuing discussions of the refinement of the Banff VCA system, the standardized form, and the development of a consensus document that would be accessible worldwide. The goal is to compile data and to review it at the Banff 2017 meeting. Categories 2 to 9 may be diagnosed concurrently and should be listed in the diagnosis in the order of their clinicopathologic significance. See Drachenberg et al (61) for morphologic definition of lesions of cell-mediated rejection and for a list of other histologic diagnoses. ABMR, antibody-mediated rejection; DSA, donor-specific antibody; TCMR, T cell-mediated rejection. Histologic features of stereotypical TCMR and ABMR, see Table 3 in Drachenberg et al (60) . 1 Arteritis is not required for the diagnosis of ABMR but can be seen in ABMR as well as TCMR. 2 Inactive chronic arteriopathy can also be included if there is evidence to suggest it is of new onset. 3 The pathology report should specify how many medium and large arteries were sampled.
